nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—Skin necrosis—Thalidomide—leprosy	0.0488	0.0488	CcSEcCtD
Metolazone—Skin exfoliation—Dapsone—leprosy	0.0318	0.0318	CcSEcCtD
Metolazone—Venous thrombosis—Thalidomide—leprosy	0.0316	0.0316	CcSEcCtD
Metolazone—Hypomagnesaemia—Thalidomide—leprosy	0.0268	0.0268	CcSEcCtD
Metolazone—Hypercalcaemia—Thalidomide—leprosy	0.0245	0.0245	CcSEcCtD
Metolazone—Petechiae—Thalidomide—leprosy	0.0207	0.0207	CcSEcCtD
Metolazone—Pancreatitis—Dapsone—leprosy	0.0205	0.0205	CcSEcCtD
Metolazone—Jaundice cholestatic—Thalidomide—leprosy	0.0194	0.0194	CcSEcCtD
Metolazone—Photosensitivity reaction—Dapsone—leprosy	0.0191	0.0191	CcSEcCtD
Metolazone—Hyperuricaemia—Thalidomide—leprosy	0.0184	0.0184	CcSEcCtD
Metolazone—Neuropathy peripheral—Dapsone—leprosy	0.0183	0.0183	CcSEcCtD
Metolazone—Blood uric acid increased—Thalidomide—leprosy	0.0174	0.0174	CcSEcCtD
Metolazone—Skin exfoliation—Thalidomide—leprosy	0.0163	0.0163	CcSEcCtD
Metolazone—Blood urea increased—Thalidomide—leprosy	0.0161	0.0161	CcSEcCtD
Metolazone—Neuropathy—Thalidomide—leprosy	0.016	0.016	CcSEcCtD
Metolazone—Tinnitus—Dapsone—leprosy	0.0156	0.0156	CcSEcCtD
Metolazone—Lightheadedness—Thalidomide—leprosy	0.0152	0.0152	CcSEcCtD
Metolazone—Photosensitivity—Thalidomide—leprosy	0.0141	0.0141	CcSEcCtD
Metolazone—Vascular purpura—Thalidomide—leprosy	0.0138	0.0138	CcSEcCtD
Metolazone—Vision blurred—Dapsone—leprosy	0.0137	0.0137	CcSEcCtD
Metolazone—Vertigo—Dapsone—leprosy	0.0131	0.0131	CcSEcCtD
Metolazone—Purpura—Thalidomide—leprosy	0.0128	0.0128	CcSEcCtD
Metolazone—Cough—Dapsone—leprosy	0.0127	0.0127	CcSEcCtD
Metolazone—Lethargy—Thalidomide—leprosy	0.0126	0.0126	CcSEcCtD
Metolazone—Hyponatraemia—Thalidomide—leprosy	0.0124	0.0124	CcSEcCtD
Metolazone—Dry skin—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Metolazone—Orthostatic hypotension—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Metolazone—Hypokalaemia—Thalidomide—leprosy	0.0113	0.0113	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Thalidomide—leprosy	0.0111	0.0111	CcSEcCtD
Metolazone—Cramp muscle—Thalidomide—leprosy	0.0111	0.0111	CcSEcCtD
Metolazone—Abdominal distension—Thalidomide—leprosy	0.0108	0.0108	CcSEcCtD
Metolazone—Insomnia—Dapsone—leprosy	0.0107	0.0107	CcSEcCtD
Metolazone—Pancreatitis—Thalidomide—leprosy	0.0105	0.0105	CcSEcCtD
Metolazone—Erectile dysfunction—Thalidomide—leprosy	0.00985	0.00985	CcSEcCtD
Metolazone—Photosensitivity reaction—Thalidomide—leprosy	0.00976	0.00976	CcSEcCtD
Metolazone—Gastrointestinal pain—Dapsone—leprosy	0.00971	0.00971	CcSEcCtD
Metolazone—Hyperglycaemia—Thalidomide—leprosy	0.00964	0.00964	CcSEcCtD
Metolazone—Drowsiness—Thalidomide—leprosy	0.00953	0.00953	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Thalidomide—leprosy	0.00945	0.00945	CcSEcCtD
Metolazone—Abdominal pain—Dapsone—leprosy	0.00939	0.00939	CcSEcCtD
Metolazone—Neuropathy peripheral—Thalidomide—leprosy	0.00934	0.00934	CcSEcCtD
Metolazone—Epistaxis—Thalidomide—leprosy	0.00899	0.00899	CcSEcCtD
Metolazone—Agranulocytosis—Thalidomide—leprosy	0.0089	0.0089	CcSEcCtD
Metolazone—Hepatitis—Thalidomide—leprosy	0.00856	0.00856	CcSEcCtD
Metolazone—Erythema multiforme—Thalidomide—leprosy	0.00809	0.00809	CcSEcCtD
Metolazone—Tinnitus—Thalidomide—leprosy	0.00798	0.00798	CcSEcCtD
Metolazone—Chills—Thalidomide—leprosy	0.00768	0.00768	CcSEcCtD
Metolazone—Vomiting—Dapsone—leprosy	0.00755	0.00755	CcSEcCtD
Metolazone—Headache—Dapsone—leprosy	0.00744	0.00744	CcSEcCtD
Metolazone—Flatulence—Thalidomide—leprosy	0.00734	0.00734	CcSEcCtD
Metolazone—Tension—Thalidomide—leprosy	0.00731	0.00731	CcSEcCtD
Metolazone—Dysgeusia—Thalidomide—leprosy	0.0073	0.0073	CcSEcCtD
Metolazone—Nervousness—Thalidomide—leprosy	0.00724	0.00724	CcSEcCtD
Metolazone—Back pain—Thalidomide—leprosy	0.00721	0.00721	CcSEcCtD
Metolazone—Muscle spasms—Thalidomide—leprosy	0.00716	0.00716	CcSEcCtD
Metolazone—Nausea—Dapsone—leprosy	0.00705	0.00705	CcSEcCtD
Metolazone—Vision blurred—Thalidomide—leprosy	0.00702	0.00702	CcSEcCtD
Metolazone—Ill-defined disorder—Thalidomide—leprosy	0.00691	0.00691	CcSEcCtD
Metolazone—Anaemia—Thalidomide—leprosy	0.00689	0.00689	CcSEcCtD
Metolazone—Agitation—Thalidomide—leprosy	0.00685	0.00685	CcSEcCtD
Metolazone—Malaise—Thalidomide—leprosy	0.00672	0.00672	CcSEcCtD
Metolazone—Vertigo—Thalidomide—leprosy	0.00669	0.00669	CcSEcCtD
Metolazone—Syncope—Thalidomide—leprosy	0.00668	0.00668	CcSEcCtD
Metolazone—Leukopenia—Thalidomide—leprosy	0.00667	0.00667	CcSEcCtD
Metolazone—Palpitations—Thalidomide—leprosy	0.00658	0.00658	CcSEcCtD
Metolazone—Loss of consciousness—Thalidomide—leprosy	0.00655	0.00655	CcSEcCtD
Metolazone—Cough—Thalidomide—leprosy	0.0065	0.0065	CcSEcCtD
Metolazone—Hypertension—Thalidomide—leprosy	0.00643	0.00643	CcSEcCtD
Metolazone—Chest pain—Thalidomide—leprosy	0.00634	0.00634	CcSEcCtD
Metolazone—Arthralgia—Thalidomide—leprosy	0.00634	0.00634	CcSEcCtD
Metolazone—Anxiety—Thalidomide—leprosy	0.00632	0.00632	CcSEcCtD
Metolazone—Discomfort—Thalidomide—leprosy	0.00627	0.00627	CcSEcCtD
Metolazone—Dry mouth—Thalidomide—leprosy	0.0062	0.0062	CcSEcCtD
Metolazone—Shock—Thalidomide—leprosy	0.00598	0.00598	CcSEcCtD
Metolazone—Thrombocytopenia—Thalidomide—leprosy	0.00595	0.00595	CcSEcCtD
Metolazone—Anorexia—Thalidomide—leprosy	0.0058	0.0058	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Thalidomide—leprosy	0.00554	0.00554	CcSEcCtD
Metolazone—Insomnia—Thalidomide—leprosy	0.0055	0.0055	CcSEcCtD
Metolazone—Paraesthesia—Thalidomide—leprosy	0.00546	0.00546	CcSEcCtD
Metolazone—Somnolence—Thalidomide—leprosy	0.00541	0.00541	CcSEcCtD
Metolazone—Dyspepsia—Thalidomide—leprosy	0.00535	0.00535	CcSEcCtD
Metolazone—Decreased appetite—Thalidomide—leprosy	0.00529	0.00529	CcSEcCtD
Metolazone—Fatigue—Thalidomide—leprosy	0.00524	0.00524	CcSEcCtD
Metolazone—Constipation—Thalidomide—leprosy	0.0052	0.0052	CcSEcCtD
Metolazone—Pain—Thalidomide—leprosy	0.0052	0.0052	CcSEcCtD
Metolazone—Feeling abnormal—Thalidomide—leprosy	0.00501	0.00501	CcSEcCtD
Metolazone—Gastrointestinal pain—Thalidomide—leprosy	0.00497	0.00497	CcSEcCtD
Metolazone—Urticaria—Thalidomide—leprosy	0.00483	0.00483	CcSEcCtD
Metolazone—Abdominal pain—Thalidomide—leprosy	0.00481	0.00481	CcSEcCtD
Metolazone—Hypersensitivity—Thalidomide—leprosy	0.00448	0.00448	CcSEcCtD
Metolazone—Asthenia—Thalidomide—leprosy	0.00436	0.00436	CcSEcCtD
Metolazone—Pruritus—Thalidomide—leprosy	0.0043	0.0043	CcSEcCtD
Metolazone—Diarrhoea—Thalidomide—leprosy	0.00416	0.00416	CcSEcCtD
Metolazone—Dizziness—Thalidomide—leprosy	0.00402	0.00402	CcSEcCtD
Metolazone—Vomiting—Thalidomide—leprosy	0.00387	0.00387	CcSEcCtD
Metolazone—Rash—Thalidomide—leprosy	0.00383	0.00383	CcSEcCtD
Metolazone—Dermatitis—Thalidomide—leprosy	0.00383	0.00383	CcSEcCtD
Metolazone—Headache—Thalidomide—leprosy	0.00381	0.00381	CcSEcCtD
Metolazone—Nausea—Thalidomide—leprosy	0.00361	0.00361	CcSEcCtD
